9 Jun 2016 14:21
Grant of options under the Horizon Discovery Group plc Long Term Incentive Plan (the "LTIP")
Cambridge, UK, 9 June 2016: Horizon Discovery Group plc (LSE: HZD), the world leader in the application of gene editing technologies, announces that, pursuant to the contractual annual grant of options under the LTIP as disclosed in the Company's AIM Admission Document dated 27 March 2014, the following LTIP options were granted today over the Company's ordinary shares of 1 pence each ("Ordinary Shares") to Directors:
Director | Number of Ordinary Shares over which options granted |
|
|
Darrin Disley | 178,269 |
Richard Vellacott | 118,846 |
The options granted have a vesting period of three years and have an exercise price of £1.56. There are no performance conditions. The LTIP options granted are equivalent to 0.3 per cent of the Company's existing issued share capital. Under the Company's LTIP plan, options will be granted to participants on an annual basis.
- ENDS -
About Horizon Discovery Group plc www.horizondiscovery.com/
Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.
Horizon's core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.
Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and in vivo models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon's commercial offering has been adopted by c1,400 unique research organisations in over 50 countries as well as in the Company's own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".
For further information from Horizon Discovery Group plc, please contact:
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Amber Fennell / Matthew Neal / Sue Stuart / Laura Thornton
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Numis Securities Limited (Joint Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
RBC Capital Markets (Joint Broker)
Paul Tomasic / Marcus Jackson
Tel: +44 (0) 20 7653 4000